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RET Proto-Oncogene Germline Mutation
in Pheochromocytoma Patients
— Incidence and Clinical Consequences
Częstość występowania i znaczenie kliniczne mutacji protoonkogenu RET
u chorych z guzem chromochłonnym
Streszczenie
Wstęp Dotychczasowe badania wskazują, że częstość ze-
społu mnogiej gruczolakowatości (MEN 2), w skład któ-
rego wchodzi guz chromochłonny, jest większa niż do-
tychczas sądzono. Zespół ten dziedziczony jest w sposób
autosomalny dominujący i wywołuje go mutacja protoon-
kogenu RET.
Celem pracy jest ocena częstości występowania oraz kli-
niczne znaczenie mutacji protoonkogenu RET u chorych
z guzem chromochłonnym.
Materiał i metody Badania genetyczne w kierunku muta-
cji protoonkogenu RET przeprowadzono u 106 chorych
(średni wiek: 49 ± 14,1 roku, 26M, 80K) z rozpoznanym
i potwierdzonym histopatologicznie guzem chromochłon-
nym.
Pacjenci ci byli uprzednio hospitalizowani i leczeni w Kli-
nice Chorób Wewnętrznych i Nadciśnienia Tętniczego
Akademii Medycznej w Warszawie w latach 1957–1998
oraz w Klinice Nadciśnienia Tętniczego Instytutu Kardio-
logii w Warszawie od roku 1980 do 2001. Oceniano rów-
nież stężenie kalcytoniny (CT), zarówno w warunkach
podstawowych, jak i po stymulacji pentagastryną, oraz stę-
żenie parathormonu.
Wyniki Obecność mutacji protoonkogenu RET wykazano
u 8 chorych (7,4%) — w eksonie 11, w kodonie 634, TGC
na CGC u 5 chorych, u pozostałych 3 odpowiednio
— w eksonie 11, kodonie 634, TGC na GGC, w eksonie
11, kodonie 634, TGC na TGG oraz w eksonie 13, kodo-
nie 791, TAT na CGC. Nadczynność komórek C potwier-
dzoną dodatnim testem pentagastrynowym stwierdzono
u 5 nosicieli, u 2 chorych wynik testu był wątpliwy, jedynie
u 1 chorego stężenie kalcytoniny było prawidłowe. Prawi-
dłowe stężenie CT obserwowano u chorego z mutacją
w eksonie 13, kodonie 791, TAT na CGC. U 4 nosicieli
potwierdzono histopatologicznie obecność raka rdzenia-
stego tarczycy (biopsja cienkoigłowa). U 3 chorych wyko-
nano totalną tyreidektomię, dwóch nie wyraziło zgody na
dalsze leczenie (w tym jeden z pozytywnym wynikiem
biopsji). Pozostali chorzy zostali poinformowani o ko-
nieczności totalnej tyroidektomii. U żadnego nosiciela nie
stwierdzono nadczynności przytarczyc.
Wnioski Wyniki badań autorów potwierdzają doniesienia
o konieczności poddawania przesiewowym badaniom ge-
netycznym oceniającym obecność mutacji protoonkogenu
RET pacjentów z guzem chromochłonnym. Potwierdzenie
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Introduction
Pheochromocytoma represents one of the forms
of secondary hypertension and accounts for 0,1–0,9%
of all cases of hypertension. The large variability of
dramatic symptoms and signs is mainly related to the
effects of high circulating levels of norepinephrine and
epinephrine secreted by the chromaffin tumour [1–3].
Recent studies have shown that the proportion
of sporadic pheochromocytoma is dramatically decre-
asing. The recent study of Neumann et al., based on
a large, unselected series of a registry of pheochromo-
cytoma, indicates that about 25% of apparently spo-
radic pheochromocytoma patients may be carriers
of mutations [4]. When hereditary, pheochromocyto-
ma can be a component of multiple endocrine neo-
plasia type 2 (MEN 2), caused by mutations of RET
gene, von Hippel-Lindau disease, caused by muta-
tions of VHL gene; and rarely, neurofibromatosis
type 1 [1–3]. Recently, mutations of the gene for suc-
cinate dehydrogenase subunit D and subunit B were
identified in another related neuroendocrine disease
with coexistence of pheochromocytoma and paragan-
gliomas of the neck or glomus tumour [4].
MEN 2 is an autosomal dominant syndrome iden-
tified to date in 500–1000 kindred. MEN2A accounts
for over 75% of MEN 2.
It has been reported that patients with MEN 2A
are predisposed to have pheochromocytoma in about
50% of affected individuals and medullary thyroid
cancer (MTC) and/or C-cell hyperplasia [CCH] in
about 95% of cases [5–7]. In patients with MEN 2A
approximately 20% may be characterised by hyperpa-
rathyroidism in addition to MTC and/or CCH [8, 9].
MEN 2B is characterised by the major neoplasms of
MEN 2A (MTC and pheochromocytoma), plus de-
creased upper/lower body ratio, a marfanoid habitus,
and mucosal and intestinal ganglioneuromatosis, but
not hyperparathyroidism.
The susceptibility gene for MEN 2, is the RET proto-
oncogene (21 exons), located on chromosome 10 (10q11.2).
Most mutations affect codon 634 [5, 7–10].
Mutations of the RET proto-oncogene, which
have been identified in all families with MEN 2, can
be used to confirm the clinical diagnosis and identify
asymptomatic family members with this syndrome.
Taking into account the current knowledge sug-
gesting that almost 25% patients with pheochromocy-
toma have a hereditary disease, it became apparent
that all patients with pheochromocytoma should be
screened for MEN 2, von Hippel-Lindau disease or
one of the syndromes associated with pheochromocy-
toma and paragangliomas. In the case of RET proto-
oncogene mutation, genetic screening should also be
performed in members of carrier families to prevent
further morbidity and mortality in patients and their
families [5, 7, 11, 12].
Therefore we evaluated the incidence of RET pro-
to-oncogene germline mutations in 106 patients with
pheochromocytoma.
Material and methods
Study design and subjects
In our study we screened for MEN 2 and clinical-
ly evaluated unrelated 106 patients with pheochro-
mocytoma (mean age: 49 ± 14,1 years, 26 male,
80 female) hospitalised and surgically treated in the
Department of Internal Medicine and Hypertension,
Warsaw School of Medicine (years 1957–1998), and
in the Department of Hypertension Institute of Car-
diology in Warsaw (years 1980/81–2001). Diagnosis
of pheochromocytoma was verified in all cases by
histological examination of the tumour removed
during surgery [3, 5, 13]. In patients with RET
proto-oncogene mutation, serum calcitonin (CT)
(basal and after pentagastrin stimulation) and se-
rum parathormone (PTH) evaluations were per-
formed.
The protocol was accepted by the Ethical Com-
mittees of the Medical University of Warsaw and the
Institute of Cardiology in Warsaw.
Molecular genetic analysis for RET gene
Genomic DNA was isolated from peripheral blo-
od lymphocytes by standard methods. Single-strand
conformation polymorphism (SSCP) analysis was
used to find point mutations, small deletions or in-
sertions. For each exon (exon 10, 11, 13 14, 15, 16)
a separate set of primers was used. PCR — amplified
nosicielstwa tej mutacji stanowi wskazanie do wykonania
totalnej tyroidektomii.
Genetyczne badania przesiewowe mogą mieć również
znaczenie w wykrywaniu zespołu MEN 2 oraz ustaleniu
dalszego postępowania u członków rodzin, u których
stwierdza się mutację protoonkogenu RET.
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fragments (20 µl) were denatured by adding 30 µl
denaturing solution (containing 95% formamide,
10 mM NaOH, 0,25% xylene cyanol, 0,25% bromo-
phenol blue) and heating to 95% C for three minutes
before chilling on ice. Denatured fragments were se-
parated on a polyacrylamide gel (GeneGel Excel
12,5/24 Kit, Amersham Biosciences). After separa-
tion at 5 or 6 W for 1,5 h the fragments were stained
with silver as described elsewhere. In case of aber-
rant bands the probes were amplified anew for sequ-
encing. In specially difficult cases aberrant bands
were cut out of the gel, dissolved in 10 mM Tris (ph
8,0) and reamplified for sequencing. All mutations
were confirmed by sequencing. Mixtures of 20 µl
contained approx. 100 ng genomic DNA, 0,2 mM of
each dNTP, 2 µM of each primer, 1,5 mM MgCl2
and 1 U Taq DNA polymerase (Amersham/Phar-
macia). PCR conditions and sets of primers have
been previously described [6, 8, 13].
Blood analysis
Parathormone was measured using an RIA of the
intact human parathyroid hormone (N-TACT from
Incstar). Calcitonin was measured using the RIA
mat-RIA Calcitonin I (from Mallinckrodt). Samples
of the pentagastrin test were taken at times 0, 2 and
5 min after injection of 0,5 mg/kg bw [12]. Plasma
concentration of catecholamines was determined by
radioenzymatic procedure using a commercial kit.
Urinary excretion of catecholamines and metabolites
was determined by fluorometric method and later by
HPLC method [11, 12].
Results
In the series of 106 patients with pheochromocyto-
ma genetic testing revealed germline mutations in
the RET proto-oncogene in 8 cases (7,4%). These
results have been included in a previously published
study [5]. Five carriers had mutations of RET proto-
oncogene in exon 11, codon 634, TGC to CGC, the
following three — in exon 11, codon 634, TGC to
GGC, exon 11, codon 634, TGC to TGG and in
exon 13, codon 791, TAT to TTT, respectively.
The age at the onset of symptoms was younger in
RET proto-oncogene mutation carriers (mean — 43,0
± 6,9 years vs. 50,0 ± 14,4 years), but the difference
was not statistically significant (p = 0,06). All of them
had a unilateral, single adrenal pheochromocytoma tu-
mour. Of all patients positive for RET mutations,
none had clinical evidence of MTC at presentation.
Hyperactivity of thyroid C-cells, suggesting MTC or
C-cells hyperplasia, was found in 5 carriers, borderli-
ne values of basal and after pentagastrin calcitonin
(CT) level were found in 2 carriers and CT concen-
tration was normal in only one patient. Normal valu-
es of CT were found in patients with mutation in
codon 791 (TAT to TTT). None of the RET gene
mutations carrier manifested hyperparathyroidism.
In four patients with RET proto-oncogene muta-
tions MTC was confirmed histopathologically in
fine-needle biopsy. In three of them total thyroidec-
tomy was performed. Two patients refused to be sur-
gically treated (one with positive result of biopsy);
the next three RET proto-oncogene germline muta-
tion carriers have been informed that prophylactic
total thyroidectomy should be considered [13]. Cha-
racteristics of pheochromocytoma patients with RET
proto-oncogene mutations are presented in table I.
In the family of a 42-year-old female index case
patient with pheochromocytoma, newly diagnosed
MTC and RET proto-oncogene mutation, RET pro-
to-oncogene germline mutations have been detected
in 10 members. Four members agreed to be admitted
and diagnosed in the Department of Internal Medi-
cine and Hypertension for MEN 2. In one of them
asymptomatic pheochromocytoma and MTC were
diagnosed and surgically treated, in a further three
family members MTC was confirmed and surgically
treated. Other affected members of the family refu-
sed further diagnostic procedures.
Discussion
We are presenting a cohort of 106 pheochromocy-
toma patients being screened for RET proto-oncoge-
ne germline mutations. RET proto-oncogene muta-
tion occurred in 8 patients (7,4%). Every carrier of
the RET proto-oncogene mutation has been infor-
med about the necessity of prophylactic total thyro-
idectomy. In our own material MTC was histopa-
thologically confirmed by fine-needle biopsy in four
cases. Three patients were surgically treated, two car-
riers refused surgery (one with positive result of the
biopsy), in three cases we are waiting for the deci-
sion, so up to now we cannot determine the frequen-
cy of MTC in our group of patients with RET proto-
oncogene germline mutations. However, the current
knowledge indicates that the penetration of the neo-
plasia in patients with RET proto-oncogene muta-
tions is virtually 100%, so there is an agreement that
RET testing should replace calcitonin testing to dia-
gnose the MEN 2A carrier and should be the only indi-
cation for total thyroidectomy. Mortality in MEN 2A
is greater from MTC than from pheochromocytoma,
so thyroidectomy is the goal therapy in all MEN 2A
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carriers to prevent or cure MTC. Therefore, there is
a consensus that all RET proto-oncogene mutation
carriers should undergo total thyroidectomy [13].
The primary secretory product of MTC is CT,
which is important only as an excellent tumour mar-
ker. CT values (basal or stimulated by pentagastrin)
are very often but not always elevated in MTC. Defi-
nitely positive pentagastrin test was found in five car-
riers, borderline in two of them, normal values of CT
were observed only in one patient. It is worth noting
that borderline pentagastrin test result was observed
in a patient with diagnosed MTC, which confirmed,
the mentioned above, limited significance of CT es-
timation as a qualification for surgery [13].
Several mutations in RET proto-oncogene have
been found in patients with MEN 2A. Approximate-
ly 93–98% of the MEN 2A families have mutations
of one of the five cysteine conserved residues in exon
10 (codon 609, 611, 618, and 620) or exon 11 (codon
634) in the extracellular domain of the RET proto-
oncogene. In addition to the common mutations,
which affect cysteine residues, some rare non-cyste-
ine mutations have been described within exon 13,
14, 15. More than 20 missense mutations associated
with MEN 2A and other neoplastic diseases such as
MEN 2B, familial medullary thyroid carcinoma
(FMTC), sporadic medullary thyroid carcinoma
were found in the RET proto-oncogene [9, 14, 15].
The aggressiveness of MTC correlates with the mu-
tated RET codon [13]. Patients with MEN 2B and/
or RET codon 883, 918, or 922 are classified as ha-
ving the highest risk from aggressiveness of MTC
(level 3), those with 611, 618, 620, or 634 of RET
codon mutation — as having a high risk for MTC
(level 2), and those carriers with RET codon 609, 768,
790, 791, 804, and 891 mutations are classified as ha-
ving the lowest risk among the three RET codon mu-
tation stratification categories (level 1) [13]. In our
material, the mutation in codon 634 occurred in 7
carriers; the most common was missense mutation
TGC to CGC (5 carriers). It has been suggested that
patients with mutation in codon 634 TGC to CGC
had a greater risk of developing parathyroid hyperacti-
vity [15]. We found no signs of hyperparathyroidism
in any of the RET mutation carriers.
The normal values of CT level (basal and after
pentagastrin stimulation) were found only in one pa-
tient with mutation in codon 791 of RET proto-on-
cogene (level 1 of the scale of MTC aggressiveness).
Recent study of Niccoli-Sire et al. indicates that the
phenotype of patients with non-cysteine RET muta-
tions is characterised by a late onset of the disease,
suggesting a delayed appearance of C-cell disease ra-
ther than a less aggressive form [16]. Therefore, in
the carriers with the lowest risk of MTC, total thyro-
idectomy is also recommended independently of CT
values.
Based on the European Study data from 300 MEN 2
patients with pheochromocytoma, a variable chrono-
logy between diagnosis of MTC and pheochromocy-
toma can be observed. Pheochromocytoma was reve-
aled first in 25% of cases, after MTC in 40% and in
35% of cases MTC and pheochromocytoma were dia-
gnosed at the same time [17]. In our group, the first
manifestation of the disease was pheochromocytoma
in all RET proto-oncogene mutation carriers.
Table I. Characteristic of RET proto-oncogene mutation carriers (data collected before
thyroidectomy)
Tabela I. Charakterystyka kliniczna nosicieli mutacji protoonkogenu  RET (dane uzyskane
przed wykonaniem tyroidektomii)
Patient Sex MTC Age RET PTH Calcitonin
confirmed (years) mutation [pg/ml] [pg/ml]
0 min 2 min 5 min
GB F 42 634 TGC/CGC 30 66 > 1000 > 1000
KK F + 47 634 TGC/GGC 54 > 1000 > 1000 > 1000
ŁL F 31 634 TGC/CGC 24 90 > 1000 > 1000
KP F + 39 634 TGC/CGC 56 15 77 89
JS F + 54 634 TGC/CGC 24 60 > 1000 > 1000
WP M + 42 634 TGC/CGC 18 > 1000 > 1000 > 1000
MS F 47 634 TGC/TGG 18 7 80 60
PG M 39 791 TAT/TTT 25 5 27 18
Range of the serum calcitonin level: normal basal values — £ 30 pg/ml
After pentagastrin administration: 30–100 pg/ml — borderline result, above 100 pg/ml — pathological result
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tion (CT) was performed in basal conditions and
after pentagastrin stimulation; parathormone level
was also determined.
Results Genetic testing revealed germline muta-
tions in the RET proto-oncogene in 8 patients
(7,4%). Carriers had mutation of exon 11, codon 634:
TGC to CGC (5 patients), exon 11, codon 634: TGC
to GGC (1 patient), exon 11, codon 634: TGC to
TGG (1 patient) and in exon 13, codon 791: TAT to
TTT (1 patient). Hyperactivity of thyroid C-cells was
found in 5 carriers, borderline values of basal and
after pentagastrin CT were found in 2 carriers and in
only one patient CT concentration was normal. In
four patients with RET proto-oncogene mutations,
MTC was confirmed histopathologically in fine-ne-
edle biopsy. In three of them total thyroidectomy was
performed. Two patients refused to be surgically tre-
ated (one with positive result of biopsy); the next
three RET proto-oncogene germline mutation car-
riers have been informed that prophylactic total thy-
roidectomy should be considered. In none of the car-
riers hyperparathyroidism was observed.
Conclusions Our study indicates that patients
with pheochromocytoma should be genetically scre-
ened for mutations of the RET proto-oncogene. The
carriers of these mutations should undergo thyro-
idectomy. In addition, genetic studies can be useful
for the screening of the carriers families.
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